Editas medicine, inc. (EDIT)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flow from operating activities
Net loss

-142,221

-133,746

-121,031

-103,328

-108,264

-109,954

-121,088

-132,449

-120,166

-120,324

-123,511

-117,932

-110,535

-97,183

-70,440

-56,825

-85,354

-72,900

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

25,608

27,243

27,254

27,394

27,925

26,598

28,328

26,096

24,088

23,364

19,069

18,292

18,475

16,881

15,050

12,417

7,658

3,513

0

0

0

Depreciation

2,970

2,800

2,974

3,086

3,177

3,300

3,108

2,953

2,820

2,700

2,454

2,051

1,646

1,202

862

713

575

471

0

0

0

Unrealized gain on corporate equity securities

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest related to facility lease obligation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Non-cash research and development expenses

-

-

-

-

-

14,442

23,942

23,942

11,442

14,500

0

0

0

-

-

-

-

-

-

-

-

Re-measurement of warrant to purchase redeemable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

87

0

0

0

-

-

-

-

Change in fair value of preferred stock tranche asset or liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

35,551

0

0

0

Changes in fair value of anti-dilutive protection liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,609

0

0

0

Changes in deferred rent

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Other non-cash items, net

1,962

2,928

3,566

4,129

4,019

3,268

2,412

1,574

799

300

-587

-890

-893

-869

0

0

0

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

1,832

388

268

-350

-931

-649

-652

-458

-14

591

-427

-375

-163

-931

0

0

0

-

-

-

-

Prepaid expenses and other current assets

3,279

495

798

1,695

1,860

3,410

2,687

1,524

1,843

596

-103

205

-268

1,306

2,187

2,145

1,603

373

0

0

0

Right-of-use assets

8,542

9,300

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other non-current assets

0

-

-

-

-

-

-

-

-

-2

-13

-24

0

-2,246

0

0

0

-

-

-

-

Accounts payable

4,415

274

1,118

-663

-2,689

1,780

-2,411

-3,897

-6,498

-1,515

3,719

2,358

12,785

3,251

1,739

-1,677

720

-1,436

0

0

0

Accrued expenses

2,764

9,485

-2,793

-2,617

-1,629

4,042

2,972

-102

953

-8,334

-1,155

3,507

-512

11,841

6,737

5,377

4,477

3,526

0

0

0

Deferred revenue

53,147

55,395

15,573

19,633

23,970

22,889

1,261

-2,353

-11,649

81,707

85,290

88,551

90,991

935

0

0

0

-

-

-

-

Operating lease liabilities

8,801

9,324

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other current and non-current liabilities

1,604

1,652

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-65,752

-40,669

-80,366

-61,323

-52,250

-45,707

-72,103

-92,239

-101,668

-9,417

1,975

12,911

29,174

-50,246

-44,577

-39,476

-9,129

-5,443

0

0

0

Purchases of property and equipment

7,601

6,167

5,891

4,584

4,461

4,754

3,628

3,442

2,414

2,059

2,446

2,407

3,206

3,493

3,218

2,695

2,069

1,431

0

0

0

Proceeds from the sale of equipment

-

102

55

68

68

37

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of marketable securities

333,875

342,183

413,334

341,474

481,388

459,370

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from maturities of marketable securities

349,500

360,500

415,000

450,500

442,500

411,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Changes in restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Net cash provided by investing activities

8,090

12,252

-4,170

104,510

-43,281

-53,087

-17,805

-33,030

-142,334

-183,810

-209,525

-181,391

-1,567

-3,473

-4,837

-4,314

-3,688

-1,431

0

0

0

Proceeds from equipment loan, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,500

0

0

0

Proceeds from offering of common stock, net of issuance costs

-

-

-

-

-

76,789

105,929

105,929

105,515

154,143

96,685

96,489

96,408

97,488

0

0

0

-

-

-

-

Proceeds from exercise of stock options

16,377

14,863

7,708

7,022

7,451

10,328

9,596

8,190

5,730

1,755

557

686

635

233

0

0

0

-

-

-

-

Payments on construction financing lease obligation

-

-

-

-

-

857

820

784

524

764

0

0

0

-

-

-

-

-

-

-

-

Net cash provided by financing activities

133,338

131,824

77,607

35,494

35,792

86,940

115,067

113,097

110,121

154,534

95,517

96,225

96,040

97,161

93,947

214,360

236,815

139,391

0

0

0

Net (decrease) increase in cash, cash equivalents, and restricted cash

75,676

103,407

-6,929

78,681

-59,739

-11,854

25,159

-12,172

-133,881

-38,693

-112,033

-72,255

123,647

43,442

44,533

170,570

223,998

132,517

0

0

0

Supplemental disclosure of cash and non-cash activities:
Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

-

-

-

47

146

250

346

394

0

0

0

Fixed asset additions included in accounts payable and accrued expenses

1,077

728

755

384

886

659

1,065

903

745

623

120

-43

-389

130

0

0

0

-

-

-

0

Cash paid in connection with operating lease liabilities

6,784

5,970

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use assets obtained in exchange of operating lease obligations

-

19,461

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Adjustment to deferred revenue for revenue adoption

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accrual of final payment fee on equipment loan and debt discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Offering expenses included in accounts payable and accrued expenses

-

-

-

-

-

92

0

0

0

-

-

-

0

-

-

0

0

-

-

-

-

Reclassification of warrants to additional paid in capital

-

-

-

-

-

-

-

-

-

-

-

-

-

376

0

0

0

-

-

-

-

Conversion of preferred stock to common stock upon closing of the initial public offering

-

-

-

-

-

-

-

-

-

-

-

-

-

199,962

0

0

0

-

-

-

-

Reclassification of liability for common stock subject to repurchase

-

-

-

-

-

4

6

9

11

11

12

11

11

11

0

0

0

-

-

-

-

Issuance of common stock for settlement of success payments (see note 7)

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-